Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Thrombocythemia, Essential 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Blast Crisis 1Anemia, Aplastic 1Amyloidosis 1

Interventions

Dexamethasone 2venetoclax 1selinexor 1daratumumab 1In Situ Hybridization, Fluorescence 1In Situ Hybridization 1Calcium Dobesilate 1Biological Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Amyloidosis × In Situ Hybridization, Fluorescence × Clear all
NCT05486481 2025-03-06

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

University of California, San Francisco

Phase 1/2 Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡